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Abstract. 
 
Many integrins mediate cell attachment to
the extracellular matrix by recognizing short tripeptide
sequences such as arginine–glycine–aspartic acid and
leucine–aspartate–valine. Using phage display, we have
 
now found that the leukocyte-speciﬁc 
 
b
 
2
 
 integrins bind
sequences containing a leucine–leucine–glycine (LLG)
tripeptide motif. An LLG motif is present on intercellu-
lar adhesion molecule (ICAM)-1, the major 
 
b
 
2
 
 integrin
ligand, but also on several matrix proteins, including
von Willebrand factor. We developed a novel 
 
b
 
2
 
 integrin
antagonist peptide CPCFLLGCC (called LLG-C4), the
structure of which was determined by nuclear magnetic
resonance. The LLG-C4 peptide inhibited leukocyte ad-
hesion to ICAM-1, and, interestingly, also to von Wille-
brand factor. When immobilized on plastic, the LLG-C4
sequence supported the 
 
b
 
2
 
 integrin–mediated leukocyte
adhesion, but not 
 
b
 
1
 
 or 
 
b
 
3
 
 integrin–mediated cell adhe-
sion. These results suggest that LLG sequences exposed
on ICAM-1 and on von Willebrand factor at sites of
vascular injury play a role in the binding of leukocytes,
and LLG-C4 and peptidomimetics derived from it
could provide a therapeutic approach to inﬂammatory
reactions.
Key words: cell adhesion • extracellular matrix • leu-
kocyte • phage display • peptides
 
Introduction
 
The migration of leukocytes through the body and the vari-
ous lymphoid organs is an essential element of the immune
system. While circulating in blood or lymphatic vessels, leu-
kocytes are in a resting and low adhesive state. However,
when leukocytes are stimulated by signals from the im-
mune system, such as exposure to an immune complex or a
chemokine gradient, their integrin adhesion receptors be-
come activated (Hemler, 1990; Hynes, 1992; Springer,
1994; Gahmberg et al., 1997). The activation of the inte-
grins is essential for the many leukocyte functions. Such
functions are, for example, binding to antigen-presenting
cells, recirculation through lymph nodes, and migration out
of the vasculature and through the extracellular matrix to
sites of inflammation. The integrin activation needs to be
tightly regulated as inappropriate leukocyte adhesion leads
to injury of normal tissues.
Leukocytes express a specific subset of the integrin fam-
ily, the 
 
b
 
2
 
 integrins, of which four members are known.
They have a common 
 
b
 
2
 
 chain (CD18), but different 
 
a
 
subunits (
 
a
 
L
 
 or CD11a, 
 
a
 
M
 
 or CD11b, 
 
a
 
X
 
 or CD11c, 
 
a
 
D
 
 or
CD11d) (Gahmberg et al., 1997). The 
 
a
 
 subunits contain a
conserved 200-residue A or I domain, which is essential
for binding of most ligands. The crystal structures of I do-
mains from the 
 
a
 
L
 
 and 
 
a
 
M
 
 subunits indicate the presence
of a cation binding site called the metal-dependent adhe-
sion site (Lee et al., 1995; Qu and Leahy, 1995). Amino
acid substitutions in this site abrogate ligand binding
(Huang and Springer, 1995; Kamata et al., 1995).
The major ligands of these integrins, the intercellular
adhesion molecules (ICAMs),
 
1
 
 belong to the Ig superfam-
ily, and five ICAMs with slightly different binding specific-
ities have been described (Simmons et al., 1988; Staunton
et al., 1989; Fawcett et al., 1992; Bailly et al., 1995; Tian et
al., 1997). The expression of ICAM-1 on endothelial cells
is subject to stimulation by inflammatory cytokines, which
enhances the 
 
b
 
2
 
 integrin–mediated adhesion of leukocytes
on endothelial cells (Springer, 1994; Gahmberg et al.,
1997). In addition to the ICAMs, fibrinogen (Languino et
al., 1993) and the iC3b complement protein (Ueda et al.,
1994; Kamata et al., 1995) are known ligands of the 
 
b
 
2
 
 inte-
grins, particularly of 
 
a
 
M
 
b
 
2
 
 (Mac-1).
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Because of the importance of the 
 
b
 
2
 
 integrins for leuko-
cyte function, antagonists of them are potential antiinflam-
matory agents. Antibodies to 
 
b
 
2
 
 integrins or ICAMs have a
therapeutic effect in animal models of immune system dis-
orders (Clark et al., 1991; Kavanaugh et al., 1994; Miya-
moto et al., 1999). Agents targeting the 
 
b
 
2
 
 integrins could
also be valuable in the development of therapeutic strate-
gies to human leukemias (Lalancette et al., 2000). How-
ever, only a few small molecule antagonists of the 
 
b
 
2
 
 inte-
grins have been described so far (Kallen et al., 1999; Kelly
et al., 1999). Lack of such compounds has prevented the
detailed examination of the role of each member of the 
 
b
 
2
 
integrin family in leukemia dissemination as well in inflam-
matory diseases. In particular, it would be desirable to de-
sign compounds that distinguish between the inactive and
active state of an integrin. Modeling of such small mole-
cule inhibitors has been hampered by the large size of the
peptide ligands developed so far. Linear peptides are often
without a well-defined structure when free in solution.
Among the few 
 
b
 
2
 
 integrin ligands discovered is the 22–
amino acid–long peptide known as P1, which was derived
from ICAM-2 (Li et al., 1993). This peptide retains the leu-
kocyte integrin–activating effect that is typical for ICAM-2
(Li et al., 1995; Kotovuori et al., 1999). Complementarity-
determining regions of anti-
 
b
 
2
 
 integrin antibodies have
been another source of ligand peptides (Feng et al., 1998).
To develop smaller peptide ligand-leads to the 
 
b
 
2
 
 inte-
grins, we have screened random peptide libraries displayed
on filamentous phage. The phage display technique has pre-
viously yielded selective peptide ligands to the integrin spe-
cies 
 
a
 
5
 
b
 
1
 
 (Koivunen et al., 1994), 
 
a
 
V
 
b
 
3
 
/
 
b
 
5
 
 (Koivunen et al.,
1995), and 
 
a
 
V
 
b
 
6
 
 (Kraft et al., 1999). Phage library screen-
ings have confirmed the earlier findings that the tripeptide
sequence arginine–glycine–aspartic acid (RGD) is a com-
mon recognition sequence of a subset of integrins (Piersch-
bacher and Ruoslahti, 1984). The leukocyte integrins 
 
a
 
4
 
b
 
1
 
and 
 
a
 
4
 
b
 
7
 
 are known to have a specificity for peptides con-
taining another type of tripeptide sequence, leucine–aspar-
tate–valine (Komoriya et al., 1991). We have now found
that the 
 
a
 
M
 
b
 
2
 
 integrin also shares the ability to recognize a
motif comprising three amino acids, thus showing a func-
tional similarity to other integrins. The tripeptide favored
by 
 
a
 
M
 
b
 
2
 
 turned out to be a previously unknown adhesion
motif, leucine–leucine–glycine (LLG). Interestingly, such
sequences are present on several adhesion proteins, such as
ICAM-1 and von Willebrand factor. We developed a no-
napeptide ligand LLG-C4, which has a compact disulfide-
restrained structure as determined by nuclear magnetic res-
onance (NMR). This biscyclic peptide is a potent inhibitor
of leukocyte cell adhesion and migration, and is a novel lead
compound for development of antiinflammatory agents.
 
Materials and Methods
 
Monoclonal Antibodies
 
Antibodies against the integrin 
 
b
 
2
 
 subunit were 7E4, 11D3, 3F9, 2E7,
1D10, and 2F3 (Nortamo et al., 1988). The anti-
 
a
 
L
 
 subunit antibodies were
TS2/4 and MEM-83 (Monosan). The antibodies OKM1, OKM10, and
MEM-170 were used against the anti-
 
a
 
M
 
 subunit, and the antibody 3.9 was
used against the 
 
a
 
X
 
 subunit (Li et al., 1993, 1995). The 
 
a
 
IIb
 
b
 
3
 
 integrin anti-
body P2 was purchased from Immunotech, and the 
 
a
 
V
 
b
 
3
 
 integrin antibody
LM609 and the 
 
b
 
1
 
 subunit antibody 6S6 were from Chemicon.
 
Peptide Synthesis
 
Peptide synthesis was carried out using Fmoc chemistry (model 433A; Ap-
plied Biosystems). Disulfides were formed by oxidation in 10 mM ammo-
nium bicarbonate buffer, pH 9, overnight. Peptides were then purified by
HPLC on an acetonitrile gradient. Generation of disulfides was confirmed
by mass spectrometry analysis. The C(1-8;3-9) and C(1-9;3-8) peptides
with the guided disulfide bridges were custom-made by Anaspec. The
ACDCRGDCFCG (RGD-4C) peptide (Koivunen et al., 1995) was ob-
tained from Dr. E. Ruoslahti (The Burnham Institute, San Diego, CA).
 
Phage Display
 
The 
 
a
 
M
 
b
 
2
 
 integrin was purified by antibody affinity chromatography from
buffy coats obtained from the Finnish Red Cross blood transfusion service
(Li et al., 1995). Integrin was diluted in TBS/1 mM MnCl
 
2
 
 and coated onto
microtiter wells using 1 
 
m
 
g/well for the first biopanning and 100, 10, and 1
ng for subsequent pannings. Biopanning was performed using CX
 
7
 
C and
CX
 
9
 
C phage libraries essentially as described (Koivunen et al., 1994). For
construction of the libraries, the single-stranded DNA encoding degenerate
sequences was converted into a double-stranded form using 5 cycles of
PCR with only the reverse primer, followed by 11 cycles in the presence of
both the reverse and forward primers. 6 
 
m
 
g of the double-stranded oligonu-
cleotide was purified using a PCR purification kit (QIAGEN) and ligated
with 42 
 
m
 
g of the Fuse5 phage vector. The number of recombinants in the
libraries was 
 
.
 
10
 
9
 
. Phage binding, elution, and subsequent amplification in
 
Escherichia coli
 
 were repeated five times, and after each panning bacterial
colonies were picked up and stored in a 10-
 
m
 
l vol of TBS in microtiter wells
at 
 
2
 
20
 
8
 
C. For direct colony sequencing, a 1-
 
m
 
l aliquot of the thawed sam-
ples was subjected to PCR with 10 pmol each of the forward primer 5
 
9
 
-
TAATACGACTCACTATAGGGCAAGCTGATAAACCGATACA-
ATT-3
 
9
 
 and the reverse primer 5
 
9
 
-CCCTCATAGTTAGCGTAAC-
GATCT-3
 
9
 
. The PCR conditions were 92
 
8
 
C for 30 s, 60
 
8
 
C for 30 s, and 72
 
8
 
C
for 60 s, and the cycle number was 35. A 1-
 
m
 
l aliquot of the PCR reaction
was taken for sequencing using 15 pmol of either one of the primers and an-
alyzed on an ABI 310 apparatus (PE Biosystems).
 
Preparation of Glutathione S-transferase 
and Fc Fusion Proteins
 
The nucleotide sequence coding for LLG-C4 was PCR amplified from
phage DNA with the primers containing a BamHI 5
 
9
 
-AGGCTCGAG-
GATCCTCGGCCGACGGGGCT-3
 
9 
 
and an EcoRI site 5
 
9
 
-AGGTCTA-
GAATTCGCCCCAGCGGCCCC-3
 
9
 
. The PCR product was purified on
an agarose gel, digested with the two restriction enzymes, and ligated into
the PGEX-2TK vector (Amersham Pharmacia Biotech). Recombinants
expressing LLG-C4-Glutathione S-transferase (GST) were verified by
DNA sequencing. LLG-C4-GST was produced in 
 
E. coli
 
 strain BL 21 and
purified by glutathione affinity chromatography followed by dialysis.
ICAM-1-Fc fusion protein containing the five ICAM-1 Ig domains was
produced in CHO cells and purified by protein A affinity chromatography
(Hedman et al., 1992) 
 
a
 
M
 
 I domain was expressed as a GST fusion protein
in 
 
E. coli
 
 and purified by affinity chromatography on glutathione-coupled
beads followed by cleavage with thrombin to release the recombinant I
domain (Ueda et al., 1994).
 
Integrin Binding Assays
 
Integrins were immunocaptured on microtiter wells that were coated with
nonspecific IgG or the subunit antibodies OKM1, MEM170, TS2/4, 2E7, or
7E4. A 200-
 
m
 
l aliquot of the buffy coat lysate in 1% octylglucoside/1 mM
MnCl
 
2
 
/TBS was allowed to incubate for 2 h at 4
 
8
 
C. The wells were then
washed five times with the octylglucoside-containing buffer. LLG-C4-GST
or GST (10 
 
m
 
g/ml) was incubated in the integrin-coated or the 
 
a
 
M
 
 I do-
main–coated wells in 25 mM octylglucoside/TBS/1 mM MnCl
 
2
 
 for 1 h. Af-
ter washing of the wells, the bound GST was determined with anti-GST an-
tibodies (Amersham Pharmacia Biotech), which were labeled with an Eu
 
3
 
1
 
chelate according to the instructions of the manufacturer (Wallac). The
Eu
 
3
 
1
 
 fluorescence was measured with a fluorometer (1230 Arcus; Wallac).
 
Cell Culture
 
The leukocytic cell lines THP-1, Jurkat, U-937, and K562 were maintained
as described (Li et al., 1995). The nonleukocytic cell lines Eahy926,
HT1080, KS6717, and SKOV-3 were as described previously (Koivunen et
al., 1999). T cells were isolated from blood buffy coats by Ficoll-Hypaque 
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centrifugation, followed by passage through nylon wool columns (Valmu
and Gahmberg, 1995). Wild-type mouse L929 cells and the 
 
a
 
X
 
b
 
2
 
 integrin–
transfected L cell line were obtained from Dr. Y. van Kooyk (University
Hospital, Nijmegen, Netherlands).
 
Cell Adhesion
 
Fibrinogen (Calbiochem), fibronectin (Boehringer), von Willebrand fac-
tor (Calbiochem), GST fusion proteins, Fc fusion proteins, or synthetic
peptides were coated on microtiter wells at a concentration of 2 
 
m
 
g in 50
 
m
 
l TBS unless otherwise indicated. The wild-type and A2 domain–deleted
recombinant von Willebrand factors (Lankhof et al., 1997) and a captur-
ing anti-von Willebrand factor antibody D
 
9
 
-D3 used for coating were pro-
vided by Drs. J.J. Sixma and Ph.G. de Groot (University Medical Center,
Utrecht, Netherlands). To prepare polymerized peptides, glutaraldehyde
(Merck) was added at a final concentration of 0.25%. The wells were satu-
rated with 5% BSA and then washed five times with PBS. Before adhe-
sion assays, cells were treated with 50 nM 4
 
b
 
-phorbol 12,13-dibutyrate
(Sigma-Aldrich) or with 200 
 
m
 
M P1 peptide (Kotovuori et al., 1999) in se-
rum-free medium for 30 min at room temperature to activate the inte-
grins. Alternatively, cells were stimulated for 60 min at 37
 
8
 
C with the
phorbol ester (50 nM) and the C(1-8;3-9) and RGD-4C peptides, each at a
2.5 
 
m
 
M concentration, after which the peptides were removed by washing
with PBS/2.5 mM EDTA. Cells (100,000 per well) were incubated in the
microtiter wells for 60 min at 37
 
8
 
C in the absence or presence of compet-
ing peptides, antibodies, or EDTA. Unbound cells were removed by gen-
tly washing with PBS and pressing the plate against paper towels. The
bound cells were determined by an assay measuring cellular phosphatase
activity (Li et al., 1995). Alternatively, the attached cells were stained with
Crystal Violet (Sigma-Aldrich) essentially as described (Mould et al.,
1995). To study T cell binding to an endothelial cell monolayer, Eahy926
endothelial cells were plated on microtiter plates at a density of 5 
 
3
 
10
 
4
cells per well and grown for 3 d. To stimulate the production of ICAM-1,
the cells were further grown for 16 h in the presence of tumor necrosis fac-
tor (TNF)-a (10 ng/ml; Roche). T cells (1.5 3 105 per well) were allowed
to bind to Eahy926 cells for 30 min at 48C, and then 15 min at 378C. The
unbound T cells were removed by immersing the microtiter plate upside
down in PBS. The bound cells were determined by the phosphatase assay.
Cell Migration
Cell migration was studied using 8-mm pore size Transwell filters (Costar).
Both the upper and lower filter surfaces were coated with fibrinogen,
LLG-C4-GST, or GST at a concentration of 40 mg/ml. Free binding sites
were blocked with 5% BSA. THP-1 cells (5 3 104 in 100 ml) were plated
on the upper compartment in 10% serum-containing medium in the ab-
sence or presence of C(1-8;3-9) or C(1-9;3-8) (200 mM). The lower com-
partment was filled with 750 ml of the same medium. After a culture for
18 h at 378C, the filters were immersed in methanol for 15 min, in water
for 10 s, and in 0.1% toluidine blue (Sigma-Aldrich) for 5 min. The filters
were then washed three to five times with water until cell staining was
clear. Cells were removed from the upper surface of the filter with a cot-
ton swab, and cells migrated on the lower surface were counted micro-
scopically. A Student’s t test was used for statistical analysis.
NMR Analysis of Peptides
For NMR structure determination, the C(1-8;3-9) peptide was dissolved in
DMSO/H2O (90/10) and C(1-9;3-8) in H2O at the concentrations of 1–3
mM. Two-dimensional spectra, acquired with spectrometers operating at
600- and 800-MHz 1H frequency, allowed us to identify 114 nuclear Over-
hauser enhancements (nOes) for C(1-8;3-9) and 85 for C(1-9;3-8) peptide.
40 structures with no restraint violations above 0.2 Å were selected from
families of 200 structures generated by simulated annealing (DYANA
program; Güntert et al., 1997).
Results
The LLG Peptide Motif Binds to a b2 Integrin
We used the CX7C and CX9C phage libraries to search for
peptide ligands to purified aMb2 integrin. After the fifth
round of selection, the CX7C library gave a 600-fold en-
richment and CX9C a 1,000-fold enrichment of phage
bound to the integrin in comparison to background. Se-
quencing of the bound phage revealed altogether only
seven different sequences, indicating selection of specific
peptides by the integrin (Table I). Four of them contained
the LLG tripeptide motif. The two sequences most
strongly enriched were CPCFLLGCC (LLG-C4) and
CWKLLGSEEEC, and these were the only clones re-
maining after searching for high affinity binders by using
low integrin-coating concentrations. Screening protein da-
tabases indicated that the LLG tripeptide sequence is
present on several adhesion proteins. Most interestingly, it
is located on the first Ig domain of ICAM-1, just preceding
the Glu-34 residue, which is critical for ICAM-1 binding to
the aLb2 integrin (Staunton et al., 1990; Stanley and Hogg,
1998). The CWKLLGSEEEC peptide showed the highest
similarity, five out of six consecutive residues being identi-
cal to the ICAM-1 sequence (Table I). The LLG tripep-
tide sequence is also contained in domains A2 and D3 of
von Willebrand factor. These LLG-containing sequences,
except that of ICAM-1, have not been reported previously
to contain potential cell attachment sites.
We focused our studies on the LLG-C4 nonapeptide be-
cause it showed higher affinity to aMb2 in phage-binding
experiments in comparison to the other clones (data not
shown). Due to the presence of four cysteine residues, the
peptide appeared to be structurally constrained by two
disulfide bonds. We first examined whether an integrin-
binding peptide could be obtained by bacterial expression
of LLG-C4 tethered to GST. The LLG-C4-GST fusion
protein, but not GST alone, had a potent activity and
bound to the aMb2 integrin in a divalent cation–sensitive
manner like a typical integrin ligand. The cation chelator
EDTA inhibited the binding of LLG-C4-GST to the inte-
grin, which was immunocaptured on microtiter wells with
the aM subunit antibodies MEM170 or OKM1 (Fig. 1 A).
Similar EDTA-inhibitable binding of LLG-C4-GST was
detected with the aLb2 integrin, which was captured with
the TS2/4 antibody. Surprisingly, EDTA only partially
inhibited LLG-C4-GST binding when the b2 subunit
antibody 2E7 was used. We have found this antibody to
stimulate leukocyte adhesion to various matrix proteins.
LLG-C4-GST binding did not differ from GST control
and was not inhibitable by EDTA, when a nonspecific IgG
was used for immunocapture (not shown).
We next studied whether the peptide can directly inter-
act with the I domain of the aMb2 integrin, the known
ligand binding site. LLG-C4-GST, examined at the con-
centrations of 0.01–100 mg/ml, showed a concentration-
dependent binding to the isolated I domain of the aM sub-
unit (Fig. 1 B). GST at the same concentrations did not
bind. The ability of the I domain to bind LLG-C4-GST
was dependent on the Mn21 cations added to the binding
medium, and chelating Mn21 with EDTA blocked the
binding (Fig. 1 C). Initially, we encountered difficulties in
chemical synthesis of an active and water-soluble LLG-
C4 peptide, apparently because mixed disulfides easily
formed during air oxidation. One LLG-C4 (1) preparation
was highly active and blocked the ability of the I domain
to bind the LLG-C4-GST (Fig. 1 C). The same peptide
was also active in cell culture experiments. Another prepa-
ration, LLG-C4 (2), was inactive apparently due to disad-The Journal of Cell Biology, Volume 153, 2001 908
vantageous disulfide bonding and did not inhibit LLG-C4-
GST binding to the I domain.
Immobilized LLG-C4 Nonapeptide Selectively 
Supports b2 Integrin–mediated Cell Adhesion
We examined the integrin-binding specificity of LLG-C4
in cell adhesion assays. Phorbol ester–activated THP-1
monocytic cells efficiently bound to LLG-C4-GST, but not
to GST or peptide-GST controls (CLRSGRGC-GST, CP-
PWWSQC-GST) coated on microtiter wells (Fig. 2 A).
EDTA at a concentration of 2.5 mM abolished the bind-
ing. Screening with a panel of antiintegrin antibodies indi-
cated that the cell adhesion on LLG-C4-GST was com-
pletely inhibited by the blocking antibody to the b2 chain,
7E4 (Fig. 2 B). Antibodies to the b1 (6S6) and b3 integrins
(LM609, P2) had no effect. Partial inhibition was obtained
with the b2 chain antibodies 11D3 and 3F9. The order of
the potency of the three b2 antibodies is the same as that
obtained previously in other assays (Nortamo et al., 1988).
We also studied the b2 chain antibodies 2E7, 1D10, and
2F3 that activate the b2 integrin–mediated cell adhesion.
In accordance, each of these antibodies stimulated THP-1
adhesion on LLG-C4-GST (data not shown).
Studies with antibodies against the integrin a subunits
showed that the aX subunit antibody 3.9 effectively inhib-
ited the THP-1 adhesion to LLG-C4-GST. The aM subunit
antibodies OKM10, MEM170, and 60.1 were weakly in-
hibitory, whereas the aL-directed antibodies TS1/22 and
TS2/4 had hardly any effect. Furthermore, we found that
the aX antibody 3.9 and the aM antibody OKM10 had a
synergistic effect when added together, causing a complete
inhibition of the cell adhesion.
THP-1 cells similarly bound strongly to the synthetic
air-oxidized LLG-C4 nonapeptide coated on plastic, and
the antibodies against the aMb2 and aXb2 integrins (3.9,
OKM10, and 7E4) prevented the binding (data not shown).
To determine the arrangement of the disulfide bonds in the
active form of LLG-C4, we prepared synthetic peptides
with different disulfide configurations. The most active
peptide, C(1-8;3-9), was obtained by directing one disulfide
Table I. Seven Phage Sequences Bound to the aMb2 Integrin 
(Mac-1) and their Alignment with LLG-containing Sequences 
Present in Cell Adhesion Proteins
CPCFLLGCC (15)
CWKLLGSEEEC (15)
CWHKDLLGC (4)
CWSMELLGC
CPPDLFWYC (4)
CPEDLYFFC (3)
CPEDFIFFC
ICAM-1 CDQPKLLGIETPL
von Willebrand factor A2 TVGPGLLGVSTLG
von Willebrand factor D3 GRYIILLGKALSV
Type I collagen-a2 PGPQGLLGAPGIL
Type IV collagen-a4 PGPPGLLGRPGEA
The amino acids that are identical to the phage peptides are shown in bold. The ICAM-1
sequence is from the first Ig domain (Simmons et al., 1988). The von Willebrand factor
sequences are from A2 and D3 domains (Lynch et al., 1985) and the type I and IV
collagen sequences are from a chains (De Wet et al., 1987; Leinonen et al., 1994). The
number of isolated nucleotide sequences encoding each peptide is indicated in
parentheses.
Figure 1. Divalent cation–dependent binding of LLG-C4 non-
apeptide to leukocyte b2 integrin and its I domain. (A) Integrin
from a blood cell lysate was immunocaptured on microtiter wells
using the aM subunit antibody MEM170 or OKM1, the aX sub-
unit antibody TS2/4, or the b2 subunit antibody 2E7. Purified
LLG-C4-GST or GST control (2 mg/well) was allowed to bind for
60 min in the absence or presence of EDTA. The bound GST
protein was determined by using anti-GST antibodies. The re-
sults show the means 6 SD from triplicate wells. The experiment
was repeated three times with similar results. (B) LLG-C4-GST
or GST was incubated in microtiter wells coated with purified aM
subunit I domain. The concentrations of GST proteins were as in-
dicated. The bound GST was determined with anti-GST antibod-
ies. The results are means 6 SD from triplicate wells. The results
were similar in two other experiments. (C) LLG-C4-GST (10 mg/
ml) was incubated in I domain–coated wells in the absence or
presence of EDTA (2.5 mM), the LLG-C4 (1) peptide (100 mM),
or the inactive LLG-C4(2) peptide (100 mM). The binding was
determined with anti-GST antibodies. The results are the means 6
SD from triplicate wells.Koivunen et al. Peptide Ligands of Leukocyte b2 Integrins 909
bond between the C1 and C8 cysteines and a second one
between the C3 and C9 cysteines. Cells bound to the C(1-8;
3-9) disulfide–containing peptide but failed to bind to the
conformer with C(1-9;3-8) disulfides (Fig. 2 C). Cross-link-
ing of the C(1-8;3-9) peptide with glutaraldehyde further
enhanced cell binding, apparently due to better coating of
the multimeric peptide. C(1-9;3-8) was inactive even after
the cross-linking. In general, the C(1-8;3-9) peptide specifi-
cally supported the binding of b2 integrin–expressing cells
lines such b2 integrin–transfected L cells and the leukocytic
cell lines THP-1, U-937, and Jurkat. The binding of aXb2-
transfected L cells to LLG-C4-GST was inhibited by
EDTA and the b2 integrin–blocking antibody 7E4 (Fig. 2
D). Nonleukocytic cell lines L929, K562, SKOV-3, KS6717,
and Eahy96, which do not express b2 integrins, showed no
binding to the peptide or LLG-C4-GST, whether the cells
were pretreated with phorbol ester or not (data not shown).
LLG-C4 Nonapeptide Specifically Blocks b2 
Integrin–mediated Adhesion of Leukocytes
We examined the ability of LLG-containing peptides to
block leukocyte binding to adhesion proteins containing
or lacking an LLG tripeptide sequence. THP-1 cell adhe-
sion on LLG-C4-GST was inhibited by the C(1-8;3-9) pep-
tide with an IC50 of 20 mM (Fig. 3 A). The other con-
former, C(1-9;3-8), was 20-fold less active than C(1-8;3-9).
To study whether the LLG tripeptide sequence is suffi-
cient for recognition by the b2 integrins, we prepared the
minimal cyclic CLLGC peptide. In a control peptide the
leucines were replaced by alanines. THP-1 cell adhesion
experiments using the LLG-C4-GST substratum indicated
that CAAGC was only a weak competitor of cell adhesion,
whereas CLLGC readily inhibited cell adhesion at concen-
trations of $1 mM, indicating a specific recognition of the
LLG motif by the b2 integrins (Fig. 3 B).
Figure 2. Immobilized LLG-C4 supports b2 integrin–directed cell adhesion. (A) Phorbol ester–activated THP-1 cells were allowed to
bind for 60 min to microtiter wells coated with LLG-C4-GST, GST, or albumin. EDTA was included at a 2.5-mM concentration. The
bound cells were determined by the assay measuring cellular phosphatase activity as described in Materials and Methods. The data are
the means 6 SD from triplicate wells. Similar results were obtained in six other experiments. (B) THP-1 cells were mixed with each an-
tibody against the b1, b2, b3, aX, aM, or aL integrin subunit as indicated. An aliquot of cells was then transferred to wells coated with
LLG-C4-GST and incubated for 60 min. The bound cells were determined by the phosphatase assay. The results are the mean percent-
age of adhesion 6 SD of two to four independent experiments, each done in triplicate wells. (C) The C(1-8;3-9) and C(1-9;3-8) peptides
were coated on microtiter wells in the absence or presence of glutaraldehyde. THP-1 cells (105 per well) were allowed to bind for 60 min
and the bound cells were determined. The results show the mean 6 SD of triplicate wells. The experiment was repeated twice. (D) The
aXb2 integrin–transfected L cells were allowed to bind to LLG-G4-GST or GST. The 7E4 antibody and EDTA were used as competi-
tors. The results, mean percentage of adhesion 6 SD, are representative of three experiments conducted in triplicate wells. The differ-
ence in the binding to LLG-C4-GST versus GST is statistically significant (P 5 0.016).The Journal of Cell Biology, Volume 153, 2001 910
We next examined the ability of LLG-containing pep-
tides to inhibit the aLb2 integrin–mediated binding of Jur-
kat cells to ICAM-1-Fc recombinant protein, which con-
tains the LLG sequence of the first Ig domain. ICAM-1-Fc
was directly coated on microtiter wells or captured via
protein A. In both cases we found concentration-depen-
dent inhibition by C(1-8;3-9) on Jurkat cell adhesion and
the IC50 was z80 mM (Fig. 4 A). The C(1-9;3-8) conformer
was severalfold less active and had hardly any effect. C(1-
8;3-9) similarly inhibited the binding of freshly isolated T
cells to cultured endothelial cells which were stimulated to
express ICAM-1 by treatment with TNF-a (Fig. 4 B). T
cells did not bind to unstimulated endothelial cells. As a
control, the RGD-C4 peptide had no effect on T cell bind-
ing to endothelial ICAM-1.
As von Willebrand factor contains LLG peptide motifs,
we were interested in the capability of the protein to func-
tion as a substratum for leukocytes. We found that phorbol
ester–activated THP-1 cells strongly bound. The b2 integrin
antibody 7E4 blocked the THP-1 cell binding to von Wille-
brand factor (Fig. 5 A) and was nearly as efficient an inhib-
itor as the cation chelator EDTA (data not shown). The b3
integrin antibodies LM609 and P2 were without effect.
C(1-8;3-9) was a potent inhibitor of THP-1 cell binding to
von Willebrand factor. The peptide inhibited with an IC50
of  z20  mM (Fig. 5 B). In addition, CLLGC but not
CAAGC inhibited at a 500 mM concentration (data not
shown). Similar C(1-8;3-9) peptide–mediated inhibition
was observed on Jurkat cell binding to von Willebrand fac-
tor (not shown). Importantly, THP-1 showed weaker bind-
ing (35% of wild-type) to a mutated von Willebrand factor,
from which the A2 domain, including the LLG sequence,
was deleted (Fig. 5 C). Furthermore, THP-1 adhesion to
the A2-deleted von Willebrand factor was not blocked by
C(1-8;3-9), but by the RGD-4C peptide. To further study
the specificity of the LLG peptides, we examined THP-1
Figure 3. Effect of guided disulfide bridges on activity of LLG-
C4. (A) THP-1 cells were mixed in suspension with peptides con-
taining the C(1-8;3-9) or C(1-9;3-8) disulfides. The final peptide
concentrations are indicated. Cells were then incubated for 60 min
in microtiter wells coated with LLG-C4-GST. The bound cells
were quantitated by the phosphatase assay. The results represent
the mean 6 SD of triplicate wells with similar results obtained in
two other experiments. (B) THP-1 cell binding to LLG-C4-GST
was examined in the presence of C(1-8;3-9), CLLGC, or
CAAGC. The bound cells were determined by the phosphatase
assay. The data show the means 6 SD from triplicate wells and
were similar in two other experiments.
Figure 4. Inhibition of leukocyte cell adhesion to ICAM-1 by
LLG-C4. (A) Jurkat cells were allowed to attach to immobilized
ICAM-1-Fc in microtiter wells in the absence or presence of the
LLG-C4 peptides. After a 45-min incubation, the unbound cells
were removed by immersing the microtiter plate upside down on
a decanter containing PBS. The attached cells were stained with
Crystal Violet. The results show the percentage of cell adhesion 6
SD derived from two experiments, each with triplicate or quadru-
plicate wells. (B) T cells were allowed to bind to TNF-a–stimu-
lated EaHy926 endothelial cell monolayers that were grown on
microtiter wells. LLG-C4 or RGD-4C was included at a concen-
tration of 50 mM. After a 45-min incubation, the unbound cells
were removed by immersing the microtiter plate in a PBS solu-
tion, and the bound T cells were determined by the phosphatase
assay. The data are the mean 6 SD of triplicate wells.Koivunen et al. Peptide Ligands of Leukocyte b2 Integrins 911
adhesion to fibronectin, a known ligand of several b1 and
b3 integrins. C(1-8;3-9) showed no significant inhibition of
fibronectin binding by THP-1 cells. C(1-8;3-9) also had
no effect on binding of nonleukocytic cell lines such as
HT1080 on fibronectin or fibrinogen (data not shown).
Finally, we examined THP-1 adhesion to fibrinogen,
which is predominantly mediated via the aMb2 and aXb2
integrins (Li et al., 1995). C(1-8;3-9) readily inhibited the
binding, whereas C(1-9;3-8) did not (Fig. 6 A). Similar re-
sults were obtained with U937 cells, which also express the
aMb2 and aXb2 integrins (data not shown). As RGD-
directed integrins can also mediate cell attachment on
fibrinogen, we compared C(1-8;3-9) to the RGD-4C pep-
tide, the selective ligand of aVb3/b5 integrins. We prestim-
ulated THP-1 cells with low concentrations of C(1-8;3-9)
and RGD-4C to fully activate both the b2 and RGD-
dependent integrins. After the peptide prestimulation,
RGD-4C inhibited THP-1 cell adhesion on fibrinogen
more effectively than C(1-8;3-9) (Fig. 6 B). To study
whether C(1-8;3-9) and RGD-4C target different inte-
grins, the peptides were given together to cells. The effects
of C(1-8;3-9) and RGD-4C were additive and the peptide
combination blocked cell adhesion efficiently.
As a model of monocyte rolling and extravasation, we
examined in vitro migration of THP-1 cells on fibrinogen
immobilized on Transwell filters. Cells effectively migrated
in the presence of 10% serum. C(1-8;3-9) at a concentra-
tion of 200 mM completely abolished the ability of the cells
to traverse the filter and bind to its lower surface (Fig. 6 C;
P 5 0.005, n 5 6). The C(1-9;3-8) conformer was less active
than C(1-8;3-9) and inhibited only partially (P 5 0.01, n 5
6). The activity difference between C(1-8;3-9) and C(1-9;3-
8) was significant (P 5 0.003). In a reverse strategy, when
the filter was coated with LLG-C4, cell migration was
strongly enhanced. Approximately 10-fold more cells mi-
grated on the LLG-C4-GST substratum than on control
GST substratum (Fig. 6 D). Cell migration on LLG-C4-
GST was also more efficient when compared with fi-
bronectin and fibrinogen coatings. C(1-8;3-9) at the 200
mM concentration completely suppressed the cell migra-
tion on LLG-C4-GST (P 5 0.0026, n 5 6; data not shown).
NMR Structures of Nonapeptide Conformers
We analyzed the C(1-8;3-9) and C(1-9;3-8) peptides by
NMR spectroscopy to determine whether there are differ-
ences in peptide conformations due to the directed ar-
rangement of the disulfide bonds. The structure determi-
nations resulted in well-defined backbone conformations.
The root mean square of deviation of the main chain at-
oms was 0.4 6 0.2 Å for C(1-8;3-9) and 0.3 6 0.2 Å for
C(1-9;3-8) calculated from ensembles of 40 structures. For
both peptides, all main chain dihedrals f and c are in the
favorable and allowed regions of Ramachandran plot.
There are only a few nOes to define the side chain orienta-
tion, and therefore the side chain dihedrals of F4, L5, and
L6, in particular, are dispersed (Fig. 7 A).
The pairing of the disulfides in the two ways influenced
the structure of the nonapeptide considerably. The “cross-
ing arrangement of disulfides” of C(1-8;3-9) constrains the
overall structure tighter than the “parallel arrangement of
disulfides” of C(1-9;3-8). This is reflected by the larger
Figure 5. THP-1 cell adhesion to von Willebrand factor is inhib-
ited by the LLG-C4 peptide. (A) THP-1 cell binding to von Wil-
lebrand factor was examined in the presence of antibodies
against the b2 (7E4), aVb3 (LM609), or aIIbb3 (P2) integrins. Af-
ter a 60-min incubation in von Willebrand factor–coated wells,
the bound cells were determined. The data are the mean 6 SD of
triplicate wells. The experiment was repeated three times. (B)
THP-1 cell binding to wild-type von Willebrand factor or fibronec-
tin in the presence of the indicated concentrations of C(1-8;3-9).
(C) Binding of THP-1 cells to domain A2–deleted von Wille-
brand factor. The binding to wild-type von Willebrand factor was
given as 100%. C(1-8;3-9) or RGD-4C was included as competi-
tor at the concentrations described. The bound cells were deter-
mined by the phosphatase assay. The data are the mean 6 SD of
triplicate wells and were similar in two other experiments.The Journal of Cell Biology, Volume 153, 2001 912
number of nOes observed for C(1-8;3-9) (114) than for
C(1-9;3-8) (85). There is no bias towards shorter distance
restraints in C(1-8;3-9) compared with those of C(1-9;3-8).
As a result of the different disulfide configurations, there
are interresidue nOes found exclusively in one of the
structures, 37 in C(1-8;3-9) and 20 in C(1-9;3-8). The cross-
ing arrangement of disulfides in C(1-8;3-9) is topologically
more complicated than the parallel bridging in C(1-9;3-8).
In the short nonapeptide the adjacent disulfides with large
van der Waals radii of sulphur atoms give rise to numerous
steric restraints. The residue P2 also limits conformational
freedom, whereas G7 contributes to it. The impact of mere
topology on the steric restraints is apparent from the rep-
resentative structures (Fig. 7 B). C(1-8;3-9) is more com-
pact than C(1-9;3-8). Furthermore, there is a continuous
hydrophobic surface patch composed of aliphatic groups
of P2, F4, and L5 in the C(1-8;3-9) peptide. Overall, the
disulfide bridges and the F4-L6 strand are buckled in C(1-
8;3-9), whereas in C(1-9;3-8) they are extended. This likely
accounts for the poorer water solubility of C(1-8;3-9) and
may contribute to its higher activity.
Discussion
We have developed highly specific peptide antagonists of
the leukocyte b2 integrins using phage display. The most
active antagonist, LLG-C4, is a biscyclic nonapeptide that
is structurally restrained by two disulfide bonds and con-
Figure 6. Synthetic LLG-C4 peptide prevents adhesion and migration of THP-1 cells on fibrinogen substratum. (A) Phorbol ester–acti-
vated THP-1 cells were administered together with C(1-8;3-9) or C(1-9;3-8), or in the absence of peptides, in microtiter wells coated with
fibrinogen. After a 60-min incubation the bound cells were determined by the phosphatase assay. The results are the mean 6 SD of trip-
licate wells and were similar in two other experiments. (B) To activate integrins, THP-1 were stimulated both with phorbol ester (50 nM)
and the RGD-4C and C(1-8;3-9) peptides (each 2.5 mM) for 1 h. After washing, the cells were allowed to bind to fibrinogen-coated wells
in the presence of C(1-8;3-9) or RGD-4C or both peptides at the concentrations indicated. After a 30-min incubation the bound cells
were determined. The results are the mean 6 SD of triplicate wells and were similar in two other experiments. At some data points the
SD values are too small to be seen. (C) Transwell filters were coated both on the upper and lower surface with fibrinogen, or left un-
coated, and then saturated with BSA. THP-1 cells were plated on the upper surface of the filter in the presence of 10% serum-containing
medium. The concentrations of C(1-8;3-9) and C(1-9;3-8) were 200 mM. After an 18-h culture, the cells migrated underneath the filter
were determined. The cells were fixed, stained, and counted under a microscope. The results show means 6 SD of at least three experi-
ments. (D) Both sides of the Transwell filters were coated with LLG-C4-GST, GST, fibrinogen, or BSA. A total of 5 3 104 THP-1 cells
were administered per filter in 10% serum-containing medium and cultured for 18 h. The number of cells migrated to the lower surface
of filter was counted microscopically. The results show means 6 SD of at least three experiments.Koivunen et al. Peptide Ligands of Leukocyte b2 Integrins 913
tains a novel LLG tripeptide adhesion motif. The LLG-C4
peptide specifically blocked the b2 integrin–mediated leu-
kocyte adhesion and inhibited leukocyte binding to their
major ligand ICAM-1. Furthermore, like a typical integrin
ligand, the peptide supported cell adhesion when immobi-
lized on plastic and bound leukocytic cell lines, but not
cells lacking b2 integrins. The effectiveness and leukocyte
specificity of the peptide are explained by its ability to in-
teract with the I domain, which is a known active site in
the leukocyte integrins. Interestingly, not only ICAM-1
but also several other adhesion proteins, including von
Willebrand factor, contain the consensus PP/XXLLG se-
quence identified by phage display.
The activity of the LLG-C4 nonapeptide was strictly de-
pendent on the correct formation of two disulfide bridges.
There was a 20-fold difference in the activities of two bis-
cyclic conformers that differed only in the configuration of
the disulfide bridges. The more active peptide had a very
compact structure due to a “crossing” arrangement of the
disulfide bonds as shown by NMR. Interestingly, the leu-
cine side chains protrude from the cyclic structure like an-
tennae, suggesting that they can directly interact with the
integrin. The small glycine residue may adjust a correct
distance between the leucine side chains.  The biscyclic
RGD-4C peptide can also exist in two different isomers,
depending on internal disulfide bonding, and the two
structures have clearly different integrin-binding activities
(Assa-Munt et al., 2001).
LLG-C4-GST is a highly efficient adhesion substratum
for phorbol ester–activated THP-1 leukemia cells. We also
detected cell binding to the immobilized nonapeptide, but
the overall binding was weaker, apparently because the
short peptide coats less efficiently on microtiter plates. We
were not able to detect a similar strong binding of the aXb2
Figure 7. Comparison of
structures of cyclic LLG-
C4 peptide conformers by
NMR. (A) Families of 40
conformations of C(1-8;3-9)
(left) and C(1-9;3-8) (right)
are shown. The heavy atoms
of the disulfide-closed back-
bones are superimposed in
each family and then the two
families are translated apart
for viewing. (B) Stereo views
of representative solution
structures C(1-8;3-9) (top)
and C(1-9;3-8) (bottom) are
shown. For this presentation
the two structures were ini-
tially superimposed on the
main chain atoms of F4, L5,
and L6, and then translated
apart for viewing. In the C(1-
8;3-9) peptide C1 pairs with
C8 above and C3 with C9 be-
low the cyclic structure.
Likewise, in the C(1-9;3-8)
peptide C1 pairs with C9
above and C3 with C8 below
the ring.The Journal of Cell Biology, Volume 153, 2001 914
integrin–transfected L cells to LLG-C4-GST as with
THP-1. This is likely due to the fact that the integrin ex-
pression was limited only to a subset of L cells as deter-
mined by FACS® analysis.
Immunocapture experiments with different b2 integrin
antibodies showed that LLG-C4 is able to bind to each of
the three integrin species, aLb2, aMb2, and aXb2. EDTA in-
hibition showed that the binding of LLG-C4 to the inte-
grins as well as to purified I domain is cation dependent.
However, one of the antibodies used for integrin immuno-
capture gave an exceptional result in that EDTA could not
completely inhibit the binding of LLG-C4-GST fusion pro-
tein. This antibody, 2E7, which recognizes the common b2
subunit, shows an integrin-activating effect in cell culture
and stimulates leukocyte cell adhesion to LLG-C4-GST
and various matrix proteins. Thus, it is possible that this
antibody changes the conformation of integrin, resulting in
stronger binding. The antibody may expose secondary
binding sites for ligands in integrins, and GST protein itself
may then contribute to the cation-independent binding.
Previous studies have indicated that synthetic peptides
spanning the LLG region of ICAM-1 (Ross et al., 1992; Li
et al., 1993) or the corresponding region of ICAM-2 (Li et
al., 1993) support leukocyte cell adhesion when the pep-
tides are immobilized on plastic. In soluble forms, the pep-
tides block binding of leukocytic cells to ICAM-1 ex-
pressed on an endothelial cell monolayer (Ross et al.,
1992; Li et al., 1995). The LLG-C4 nonapeptide is signifi-
cantly smaller than the peptide ligands described previ-
ously for the b2 integrins, and showed high activity, though
lacking a negatively charged amino acid residue such as
glutamate. Also, the pentapeptide CLLGC inhibited cell
adhesion. Thus, b2 integrin–targeting ligands can be con-
structed based on the noncharged LLG motif. This is in ac-
cordance with the crystal structures and structural models
of the first Ig domain of ICAM-1, where the LLG se-
quence is seen as part of a short b strand apparently capa-
ble of directly contacting with an integrin I domain (Bella
et al., 1998; Casasnovas et al., 1998). Alanine-scanning mu-
tagenesis studies of individual amino acids within the first
Ig domain of ICAM-1 have shown that the LLG region is
important for the integrin binding of ICAM-1. Mutation of
one of the leucine’s residues decreases ICAM-1 binding
activity partially and mutation of the glycine completely
(Fisher et al., 1997). Because of the inactivity of the gly-
cine-mutated ICAM-1, it has been suggested that the gly-
cine residue does not play a structural role, but rather di-
rectly interacts with the integrin (Fisher et al., 1997).
Mutations of the corresponding valine and glycine amino
acids to alanines in ICAM-2 also give proteins with im-
paired integrin-binding activity (Casasnovas et al., 1999).
Mutation of leucine to alanine can be considered a conser-
vative substitution, which could explain the only marginal,
though significant, decrease in the activities this substitu-
tion causes in ICAM-1 and the synthetic peptides.
von Willebrand factor contains two LLG sequences, but
an ability of these sequences to interact with integrins has
not been reported. von Willebrand factor is a multifunc-
tional adhesive ligand binding several proteins, and it pre-
vents bleeding during vascular injury by mediating platelet
adhesion to exposed subendothelium (Savage et al., 1998).
It contains two RGD sequences, at least one of which is
important in binding the platelet integrin aIIbb3 (Weiss et
al., 1993; Savage et al., 1996). We found that phorbol es-
ter–activated leukocytic cells can bind to von Willebrand
factor in an RGD-independent manner. Under these cir-
cumstances, leukocyte binding to wild-type von Wille-
brand factor was inhibited by the b2 integrin–targeting
LLG peptides and by the b2 integrin–blocking antibody
7E4, but not by antibodies against the b3 integrins. When
the whole A2 domain of von Willebrand factor, including
the LLG motif, was deleted, leukocytic cells showed much
weaker binding and the LLG-C4 peptide was not inhibi-
tory. It is notable that, besides the LLG sequences, von
Willebrand factor contains I domains (Colombatti et al.,
1993; Perkins et al., 1994) similar to those present in the a
subunits of the b2 integrins (Li et al., 1995; Qu and Leahy,
1995). Thus, it is possible that there are intra- or intermo-
lecular interactions between the LLG sequences and adja-
cent I domains, affecting the folding of the protein. If such
interactions occur, they could in part explain the inactivity
of the plasma form of von Willebrand factor. Our results
suggest that leukocytes can bind to the immobilized form
of von Willebrand factor, such as that present in vascular
subendothelium or other surfaces, and these interactions
could play a role in the initial phases of inflammation.
As the b2 integrins exist in an inactive state and become
activated only after physiologic stimuli, such as by che-
mokines or through contact with antigen-presenting cells,
it would be desirable to develop compounds binding pref-
erentially to cells bearing the activated integrins. We
found that LLG-C4 exhibits such properties and reacts
with cells after integrin activation. Furthermore, LLG-C4
is a promising b2 integrin–targeting agent, as the sequence
can specifically direct phage binding to b2 integrin–
expressing cell lines, and low concentrations of the soluble
peptide inhibit the binding (Koivunen, E., R. Pasqualini,
and W. Arap, manuscript in preparation). Finally, the
presence of LLG sequences in von Willebrand factor sug-
gests a novel function for the protein in mediating not only
platelet but also leukocyte adhesion.
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